Category Archives: Parkinson’s Treatment

Company developing investigational treatment for both newly diagnosed patients and those with a more advanced form of the disease in need of adjunctive therapy BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the first participants have been dosed in all three of the clinical trials in their Phase 3 program evaluating tavapadon in patients with Parkinsons disease. Continue reading →

Parkinsons UK has partnered with University College London (UCL) and will invest 1m in a phase II clinical trial to investigate if the drug ondansetron can alleviate hallucinations in people with Parkinsons disease. Continue reading →

NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host a virtual R&D Day on Friday, October 30, 2020 at 11:30 AM Eastern time, to discuss the Companys AXO-Lenti-PD gene therapy for Parkinsons disease. Continue reading →

October 27, 2020 07:00 ET | Source: Prevail Therapeutics NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. Continue reading →

Data Bridge Market Research has recently published the Global research Report TitledParkinsons Disease Treatment Market. The Parkinsons Disease Treatment Market report gives acquaintance about all the recent developments, product launches, joint ventures, mergers and acquisitions by several key players and brands while also giving a synopsis of market definition, classifications, and market trends. It lends a hand to companies to take decisive actions to deal with threats in a niche market Continue reading →

Meet the Doctors of Memorial Hermann The Woodlands Medical Center who share information and experience on Deep Brain Stimulation, a surgical treatment option for patients suffering from Parkinsons disease and essential tremors. Watch the video below with the Hello Woodlands interview with Dr. Allison Boyle and Dr. Continue reading →

Lukassek/Shutterstock Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio). Bayer is paying $2 billion upfront for AskBio's AAV-based gene therapy pipeline of treatments for Pompe disease, among others, and could pay an additional $2 billion in potential milestones. AskBios Pro10 AAV manufacturing process has become something of a standard across the industry Continue reading →

UCB Scope of the Parkinsons Disease Treatment Market Report: This report studies the Parkinsons Disease Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Parkinsons Disease Treatment market by product type and applications/end industries. There is no cure for Parkinsons disease, with treatment directed at improving symptoms. Continue reading →

Mauryce Caesar/Shutterstock Two years ago, Cerevel Therapeutics spun out of Pfizer. It then took an unusual approach, merging with a special purpose acquisition company, Arya Sciences Acquisition Corp II. Arya was designed specifically to acquire or merge with another company. Continue reading →

October 15, 2020 08:00 ET | Source: Newscope Capital Corporation TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (Pharmather or the Company) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that the Company has entered into an exclusive license agreement with the University of Arizona for the development and commercialization of ketamine in the treatment of Parkinsons disease. Pharmather will seek U.S Continue reading →